GENETIC PREDICTORS OF THIAZOLIDINEDIONE RESPONSE

噻唑烷二酮反应的遗传预测因子

• 批准号: 7719537
• 负责人: CHRISTINA L AQUILANTE
• 金额: $ 0.13万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719537
• 关键词: 2,4-thiazolidinedione; Affect; Blood; Blood Glucose; Cholesterol; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; DNA; Drug Interactions; Funding; Gemfibrozil; Genetic; Grant; Institution; Non-Insulin-Dependent Diabetes Mellitus; Persons; Pharmaceutical Preparations; Pioglitazone; Purpose; Research; Research Personnel; Resources; Source; Takeda brand of pioglitazone hydrochloride; Thiazolidinediones; United States Food and Drug Administration; United States National Institutes of Health; Work; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Pioglitazone (Actos) is approved by the Food and Drug Administration (FDA) and is used for the treatment of type 2 diabetes. People differ in the way they respond to pioglitazone. It is an effective medication for some people, but it does not work as well in other people. This may be a result of differences in the amount of pioglitazone in the blood. This may be due to differences in the way the drug is broken-down in the body. The way a medication is broken-down in the body may be affected by a person s genetic make-up (or DNA). The purpose of the first part of this clinical study is to determine if a person s genetic make-up affects the amount of pioglitazone in the blood and the blood sugar-lowering response to pioglitazone. This study will be undertaken in people with type 2 diabetes. The second part of this clinical study is looking at how a person s genetics affects drug interactions. The drug interaction that will be studied is pioglitazone and gemfibrozil (Lopid). Gemfibrozil is a popular cholesterol-lowering medication. When given in combination with pioglitazone, gemfibrozil increases the blood levels of pioglitazone. However, this effect is not consistent among all people. Some people have much larger increases in pioglitazone blood levels than other people. The purpose of this study is to see if genetics influences the extent to which gemfibrozil increases pioglitazone blood levels. This study will be undertaken in healthy people without type 2 diabetes.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 吡格列酮（Actos）是由食品和药物管理局（FDA）批准，用于治疗2型糖尿病。 人们对吡格列酮的反应方式不同。 它对某些人来说是一种有效的药物，但对其他人来说效果并不好。 这可能是血液中吡格列酮含量差异的结果。 这可能是由于药物在体内分解的方式不同。 药物在体内分解的方式可能会受到一个人的基因组成（或DNA）的影响。 本临床研究的第一部分的目的是确定一个人的遗传组成是否影响血液中吡格列酮的含量和对吡格列酮的降血糖反应。 这项研究将在2型糖尿病患者中进行。 这项临床研究的第二部分是研究一个人的遗传学如何影响药物相互作用。 将研究的药物相互作用是吡格列酮和吉非罗齐（Lopid）。 吉非罗齐是一种常用的降胆固醇药物。 当与吡格列酮联合给药时，吉非罗齐会增加吡格列酮的血药浓度。 然而，这种影响并不是所有人都一致的。 有些人的吡格列酮血药浓度比其他人高得多。 本研究的目的是观察基因是否影响吉非罗齐增加吡格列酮血药浓度的程度。 这项研究将在没有2型糖尿病的健康人群中进行。